KRAS and familial pancreatic carcinoma: Nevertheless, with the rise in the development and clinical investigation of inhibitors against KRAS mutations in cancers,3 it is notable that Savage et al. identified 5 promising neoepitopes candidates from KRAS mutations across lung, colon, uterine, and pancreatic cancers for drug-targeting.